Authors: Bortolotti D, Gentili V, Rizzo S, Rotola A, Rizzo R PMID: 32859121 PMCID: PMC7563485 DOI: 10.3390/cells9091975 Abstract Natural killer cells are important in the control of viral infections. However, the role of NK cells during severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has previously not been identified. Peripheral blood NK cells from SARS-CoV [...]

Authors: Mudatsir M, Yufika A, Nainu F, Frediansyah A, Megawati D doi: https://doi.org/10.3390/scipharm88030036 Abstract The coronavirus disease 2019 (COVID-19) pandemic is a major global threat. With no effective antiviral drugs, the repurposing of many currently available drugs has been considered. One such drug is ivermectin, an FDA-approved antiparasitic agent that has been shown to exhibit [...]

Authors: Pujadas E, Chaudhry F, McBride R, Richter F, Zhao S PMID: 32771081 PMCID: PMC7836878 DOI: 10.1016/S2213-2600(20)30354-4 Abstract Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) detection platforms currently report qualitative results. However, technology based on RT-PCR allows for calculation of viral load, which is associated with transmission risk and disease severity in other viral illnesses.1 [...]

Approximately 9 months of the severe acute respiratory syndrome coronavius-2 (SARS-CoV-2 [COVID-19]) spreading across the globe has led to widespread COVID-19 acute hospitalizations and death. The rapidity and highly communicable nature of the SARS-CoV-2 outbreak has hampered the design and execution of definitive randomized, controlled trials of therapy outside of the clinic or hospital.

Authors: Kwon PS, Oh H, Kwon SJ, Jin W, Zhang F, Fraser K et al. PMID: 32714563 PMCID: PMC7378085 DOI: 10.1038/s41421-020-00192-8 Abstract COVID-19, caused by the SARS-CoV-2 virus, has now spread worldwide with catastrophic human and economic impacts and currently has infected over 10 million people and killed over 500,0001. In an effort to mitigate [...]

Authors: Kim SY, Jin W, Sood A, Montgomery DW, Grant OC, Fuster MM PMID: 32653452 PMCID: PMC7347485 DOI: 10.1016/j.antiviral.2020.104873 Abstract Severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) has resulted in a pandemic and continues to spread around the globe at an unprecedented rate. To date, no effective therapeutic is available to fight its associated disease, [...]

Authors: Hannan A, Rahman A, Rahman S, Sohag AA, Dash R, Uddin J. PMID: 32659267 PMCID: PMC7351063 DOI: 10.1016/j.imlet.2020.07.001 Abstract Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is the causative pathogen of deadly Coronavirus disease-19 (COVID-19) pandemic, which emerged as a major threat to public health across the world. Although there is no clear gender or [...]

Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) represents an emergent global threat which is straining worldwide healthcare capacity. As of May 27th, the disease caused by SARS-CoV-2 (COVID-19) has resulted in more than 340,000 deaths worldwide, with 100,000 deaths in the US alone. It is imperative to study and develop pharmacological treatments suitable for the prevention and treatment of COVID-19. Ascorbic acid is a crucial vitamin necessary for the correct functioning of the immune system. It plays a role in stress response and has shown promising results when administered to the critically ill. Quercetin is a well-known flavonoid whose antiviral properties have been investigated in numerous studies. There is evidence that vitamin C and quercetin co-administration exerts a synergistic antiviral action due to overlapping antiviral and immunomodulatory properties and the capacity of ascorbate to recycle quercetin, increasing its efficacy. Safe, cheap interventions which have a sound biological rationale should be prioritized for experimental use in the current context of a global health pandemic. We present the current evidence for the use of vitamin C and quercetin both for prophylaxis in high-risk populations and for the treatment of COVID-19 patients as an adjunct to promising pharmacological agents such as Remdesivir or convalescent plasma.

Authors: Guan W, Ni Z, Hu Y, Liang W, Ou C, He J PMCID: PMC7266766 doi: 10.1016/j.jemermed.2020.04.004 Abstract The novel coronavirus (SARS-CoV-2, causing COVID-19) was originally isolated in Wuhan, China. This virus spread quickly throughout many countries in Asia and now Europe, Australia, North America, leading the World Health Organization to declare COVID-19 a pandemic. [...]

This article summarizes the likely benefits of melatonin in the attenuation of COVID-19 based on its putative pathogenesis.